2025-10-03 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided information. The report is in English, includes key numbers, and offers insights based on the data.

## Johnson & Johnson (JNJ) Stock Analysis

**Company Overview:** Johnson & Johnson (JNJ) is a global healthcare company engaged in the research, development, manufacture, and sale of a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 40.98%
*   **VOO Cumulative Return:** 97.56%
*   **Spread (JNJ - VOO):** -56.59%
*   **Spread Range:** Max: 16.6, Min: -65.5
*   **Relative Spread:** 10.8

**Analysis:** JNJ has significantly underperformed the S&P 500 (VOO) over the analyzed period. The relative spread of 10.8 indicates that the current underperformance is near the lower end of its historical range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2015-2017  | 26.0%  | 66.8%  | -2.0%   | -0.1   | 336.6  |
| 2016-2018  | 14.0%  | 10.7%  | -1.0%   | 0.1    | 310.9  |
| 2017-2019  | 20.0%  | 71.5%  | -2.0%   | 0.4    | 351.4  |
| 2018-2020  | 19.0%  | 79.2%  | -4.0%   | 0.4    | 379.1  |
| 2019-2021  | 33.0%  | 79.2%  | -14.0%  | 0.5    | 412.1  |
| 2020-2022  | 8.0%   | 79.6%  | 9.0%    | 0.4    | 425.6  |
| 2021-2023  | -19.0% | 79.6%  | -20.0%  | 0.3    | 377.6  |
| 2022-2024  | -32.0% | 79.6%  | -53.0%  | 0.3    | 348.4  |
| 2023-2025  | 12.0%  | 79.6%  | -50.0%  | 0.1    | 440.0  |

**Analysis:**

*   **Alpha:** Generally negative alpha values indicate that JNJ has consistently underperformed its benchmark (likely the S&P 500) on a risk-adjusted basis in most periods. The negative alphas in recent years (-53.0%, -50.0%) are particularly concerning.
*   **Beta:** Beta values range from -0.1 to 0.5, suggesting that JNJ has historically been less volatile than the market. A beta close to 0 indicates a low correlation with the market's movements.
*   **CAGR:** Fluctuates significantly over the periods.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, reaching up to 79.6%, indicating significant potential for losses during downturns.
*   **Cap(B):** Market capitalization shows growth over time, but the recent values suggest a decline.

### 2. Recent Stock Price Movements

*   **Current Price:** 182.64
*   **Last Market Data:** {'price': 185.98, 'previousClose': 186.05, 'change': -0.04}
*   **5-day Moving Average:** 178.64
*   **20-day Moving Average:** 177.42
*   **60-day Moving Average:** 171.86

**Analysis:** The current price is above all three moving averages, suggesting an upward trend in the short to medium term. The last market data shows a slight decrease, indicating minimal change.

### 3. Technical Indicators and Signals

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 62.83 (Approaching overbought territory, but not yet there)
*   **PPO:** 0.0984 (Positive, indicating an upward trend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (688 shares - Very Safe - MRI:0.90)
*   **Recent (20-day) Relative Spread Change:** 3.0 (+) - short-term increase.
*   **Expected Return (%):** -167.7 (Significant underperformance compared to S&P 500 in the long term)

**Analysis:** The MRI suggests a high recommendation for investment based on risk. The RSI is neutral to slightly bullish. The PPO confirms an upward trend. The hybrid signal recommends a full investment, reflecting the high MRI. The recent increase in relative spread indicates short-term improvement, but the expected return is very negative, signaling potential long-term underperformance relative to the S&P 500. The small change in the last market data doesn't point to any significant volatility.

### 4. Recent News & Significant Events

*   **USOP Names Johnson & Johnson Its Official Vendor for Total Joint Products:** Positive news indicating business expansion.
*   **Johnson & Johnson (JNJ) Is Leading The Industry In Cancer Treatments:** Positive recognition in a key therapeutic area.
*   **Johnson & Johnson (JNJ) Gains FDA Nod for TREMFYA Subcutaneous Therapy:** Positive news indicating regulatory success and product innovation.
*   **Analyst Report: Johnson & Johnson (Morningstar Research):** (Need to access the report for detailed analysis)

**Analysis:** Recent news is largely positive, focusing on new partnerships, recognition in cancer treatments, and FDA approvals, which can positively influence investor sentiment.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean = 2.17 on a 1-5 scale)
*   **Target Price:** Average: 180.60, High: 210.00, Low: 155.00

**Analysis:** The analyst consensus is "Buy" with an average target price slightly below the current price. There have been no rating changes.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-07-24 | 2.3  | 23.74 B$  |
| 2025-04-23 | 4.57 | 21.89 B$  |
| 2024-10-23 | 1.12 | 22.47 B$  |
| 2024-07-25 | 1.95 | 22.45 B$  |
| 2025-07-24 | 1.95 | 22.45 B$  |

**Analysis:** Earnings Per Share (EPS) and revenue have fluctuated. The most recent quarter (2025-07-24) shows an EPS of 2.3 and revenue of $23.74B. There is a duplicate entry for 2025-07-24 with an EPS of 1.95 and revenue of $22.45B, which might be an error and should be verified.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $23.74B    | 67.87%        |
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |
| 2024-06-30   | $22.45B    | 69.40%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-06-30   | $78.47B    | 7.06%     |
| 2025-03-31   | $78.11B    | 14.08%    |
| 2024-12-31   | $71.49B    | 4.80%     |
| 2024-09-30   | $70.16B    | 3.84%     |
| 2024-06-30   | $71.54B    | 6.55%     |

**Analysis:**

*   **Revenue:** Revenue has been relatively stable in the range of $21.89B to $23.74B.
*   **Profit Margin:** Profit margins are consistently high, ranging from 66.40% to 69.40%, demonstrating strong profitability.
*   **Equity:** Equity has generally increased, indicating financial stability.
*   **ROE:** Return on Equity (ROE) has fluctuated, with the highest value at 14.08% and the lowest at 3.84%.

### 7. 종합 Analysis (Summary)

Johnson & Johnson (JNJ) shows a mixed picture.

*   **Underperformance:** JNJ has significantly underperformed the S&P 500. The negative alpha values and extremely negative long-term expected return further emphasize this underperformance.
*   **Recent Performance:** The current stock price is trending upward, and recent market data shows minimal change.
*   **Technical Indicators:** The MRI suggests high investment recommendation based on risk. The RSI is neutral to slightly bullish. The PPO confirms an upward trend.
*   **News & Analyst Sentiment:** Recent news is positive.
*   **Financials:** JNJ has shown stable revenue, high profit margins, and positive equity.
*   **Warning:** High MDD
*   **Recommendation:** JNJ appears to be a relatively safe stock, but is currently facing a high risk, and long-term returns for this stock will be much lower than S&P 500

